NXL Insider Trading Activity and SEC Form 4 Filings
NXL insider trading summary
No open-market insider purchases or sales of Nexalin Technology, Inc. (NXL) have been reported on SEC Form 4 in the past 12 months.
Latest NXL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 12, 2025 | Carolyn Hamby Shelton | Sr. VP - Quality, Regulatory | Buy | $13K (6,000 @ $2.20) |
| Feb 4, 2025 | David Owens | Chief Medical Officer | Buy | $3K (1,000 @ $3.10) |
| Feb 4, 2025 | David Owens | Chief Medical Officer | Buy | $3K (1,000 @ $2.98) |
| Jan 28, 2025 | David Owens | Chief Medical Officer | Buy | $4K (1,500 @ $2.70) |
| Jan 23, 2025 | David Owens | Chief Medical Officer | Buy | $3K (1,000 @ $2.70) |
| Jan 13, 2025 | David Owens | Chief Medical Officer | Buy | $5K (2,000 @ $2.50) |
| Oct 28, 2024 | David Owens | Chief Medical Officer | Buy | $1K (500 @ $2.19) |
| Aug 13, 2024 | David Owens | Chief Medical Officer | Buy | $950 (1,000 @ $0.95) |
| Jun 28, 2024 | David Owens | Chief Medical Officer | Buy | $2K (1,000 @ $1.75) |
| Jun 18, 2024 | David Owens | Chief Medical Officer | Buy | $1K (1,619 @ $0.71) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.